SLC22A17 Antibody, HRP conjugated

1. Results showed the expression levels of NGAL and NGALR significantly downregulated in clear cell renal cell carcinoma samples. PMID: 30138675
2. Biochemical and Structural Characterization of the Interaction between the Siderocalin NGAL/LCN2 (Neutrophil Gelatinase-associated Lipocalin/Lipocalin 2) and the N-terminal Domain of Its Endocytic Receptor SLC22A17. PMID: 26635366
3. Lipocalin 2 might restore the health and regeneration potential of MSCs by decreasing senescence PMID: 24452457
4. No significant difference was found in the expressions of NGALR mRNA in placenta among moderate preeclampsia group, severe preeclampsia group and control group. PMID: 22932106
5. NGAL and NGALR expression might be served as novel prognostic factors and potential therapeutic targets in Hepatocellular carcinoma. PMID: 22728279
6. This study suggested that NGAL and NGALR expression are frequently up-regulated in gliomas, and are closely associated with poor clinical outcome. PMID: 21184133
7. These results suggested that SLC22A17, in cooperation with LCN2, to be involved in the acquisition of aggressive behavior among endometrial carcinoma cells. PMID: 21763306
8. Neutrophil gelatinase-associated lipocalin receptor (NGALR) is differentially expressed in human glomerular disease and is significantly up-regulated by Il-1beta in HMC via MAPK/ERK activation. PMID: 21305251
9. NGALR hypomethylation contributes to its expression in esophageal carcinomas and that this overexpression may play a role in the pathogenesis of esophageal carcinomas. PMID: 19047093

Show More

Hide All

HGNC: 23095

OMIM: 611461

KEGG: hsa:51310

STRING: 9606.ENSP00000206544

UniGene: Hs.373498